Vernakalant
CAS: 794466-70-9
Ref. 3D-FV170112
1mg | Ausgelaufen | ||
2mg | Ausgelaufen | ||
5mg | Ausgelaufen | ||
10mg | Ausgelaufen | ||
25mg | Ausgelaufen |
Produktinformation
- 3-Pyrrolidinol, 1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-, (3R)-
- (3R)-1-[(1R,2R)-2-[2-(3,4-Dimethoxyphenyl)ethoxy]cyclohexyl]-3-pyrrolidinol
Vernakalant is a novel, experimental drug that has been shown to be effective in the treatment of atrial fibrillation. Vernakalant binds to and blocks the action of calcium channels in the heart muscle. This mechanism of action prevents the rapid and excessive contractions that are characteristic of atrial fibrillation. Vernakalant also reduces blood pressure by inhibiting angiotensin II-mediated vasoconstriction. The drug is currently being tested as a pharmacological treatment for structural heart disease and congestive heart failure.